Eledon Pharmaceuticals, Inc. · NASDAQ:ELDN
Eledon Pharmaceuticals — Technical Presentation
18 slides from Eledon Pharmaceuticals's technical presentation
Slide 1: Patient-reported outcomes in the Phase 2 BESTOW trial comparing tegoprubart to tacrolimus
Patient-reported outcomes in the Phase 2 BESTOW trial comparing tegoprubart to tacrolimus in kidney transplant recipients Andrew Adams Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, USA
Slide 2: BESTOW: a prospective, multicenter, active-controlled, randomized, open-label Phase 2 trial
BESTOW: a prospective, multicenter, active-controlled, randomized, open-label Phase 2 trial • BESTOW (NCT05983770) was a head-to-head comparison of tacrolimus (calcineurin inhibitor) and tegoprubart (anti-CD40L antibody) in de novo kidney transplant recipients • Alongside safety and efficacy outcome
Slide 3: BESTOW: Safety and efficacy findings
BESTOW: Safety and efficacy findings • Tegoprubart preserved kidney function eGFR was higher with tegoprubart than tacrolimus BESTOW BESTOW EXTENSION across all measurable time points, including amongst 90 Mean (±SEM) eGFR (mL/min/1.73 m2) * * * patients with rejection who continued treatment 80 70
Slide 4: BESTOW: Safety and efficacy findings
BESTOW: Safety and efficacy findings BESTOW BESTOW EXTENSION • Tegoprubart preserved kidney function eGFR was higher with tegoprubart than tacrolimus across all measurable time points, including amongst patients with rejection who continued treatment • Tegoprubart adequately controlled rejection BPA
Slide 5: BESTOW: Safety and efficacy findings
BESTOW: Safety and efficacy findings Most frequently occurring TEAEs (≥ 10% by PT) Cytomegalovirus viremia Leukopenia • Tegoprubart preserved kidney function Anemia Diarrhea eGFR was higher with tegoprubart than tacrolimus Constipation Hypophosphatemia across all measurable time points, including am
Slide 6: BESTOW: Health-Related Quality of Life (HRQoL)
BESTOW: Health-Related Quality of Life (HRQoL) • Kidney transplantation impacts patient HRQoL1 Study Aim Treatment burden Symptoms that impact physical functioning Clinical outcomes Ongoing psychological distress, with emotional and social impact improved with tegoprubart treatment • PROs Useful for
Slide 7: Tegoprubart showed early improvement in patient-reported HRQoL sustained at Month 12 (1 of 3)
Tegoprubart showed early improvement in patient-reported HRQoL that was sustained at Month 12 (1 of 3) Burden of kidney disease Effects of kidney disease • KDQOL-SF: timelinea scale on daily life scale HRQoL improvements were 100 100 observed across all 5 subscales 80 90 with tegoprubart, and 4 of 5
Slide 8: Tegoprubart showed early improvement in patient-reported HRQoL sustained at Month 12 (2 of 3)
Tegoprubart showed early improvement in patient-reported HRQoL that was sustained at Month 12 (2 of 3) Symptoms and problems SF-12 physical component • KDQOL-SF: timelinea scale summary 60 HRQoL improvements were 100 observed across all 5 subscales Mean (±SEM) at Month 12 with tegoprubart, and 4 of
Slide 9: Tegoprubart showed early improvement in patient-reported HRQoL sustained at Month 12 (3 of 3)
Tegoprubart showed early improvement in patient-reported HRQoL that was sustained at Month 12 (3 of 3) SF-12 mental component summary • KDQOL-SF: timelinea 60 HRQoL improvements were observed across all 5 subscales 55 with tegoprubart, and 4 of 5 subscales with tacrolimus Score 50 HRQoL improved by
Slide 10: Tegoprubart showed greater improvement in key HRQoL measures at Month 12
Tegoprubart showed greater improvement in key HRQoL measures at Month 12 • KDQOL-SF: change from baselinea Symptoms and problems: greater improvement with tegoprubart vs tacrolimus (9.0 vs 3.3; p < 0.05) SF-12 mental component summary: improved with tegoprubart (+1.5) but declined with tacrolimus (−
Slide 11: Symptom occurrence decreased over time with tegoprubart
Symptom occurrence decreased over time with tegoprubart MTSOSD-59R Total MTSOSD-59R Scores represent symptom occurrence Tacrolimus: total symptom occurrence initially decreased (higher scores reflect greater symptom occurrence) through Month 6, but then rebounded to baseline levels by Month 12 50 Me
Slide 12: MTSOSD-59R: Symptoms getting better (1 of 3)
MTSOSD-59R: Symptoms getting better (1 of 3) Participants with occurence (%) Neurological Difference in occurence (%) For symptoms with the greatest between-group difference in altered voice improvement, greater concentration/memory problems improvements (i.e. decreased symptom occurrence) were ting
Slide 13: MTSOSD-59R: Symptoms getting better (2 of 3)
MTSOSD-59R: Symptoms getting better (2 of 3) Gastrointestinal/metabolic For symptoms with the greatest between-group difference in tiredness improvement, greater increased thirst improvements (i.e. decreased stomach complain/nausea/vomiting symptom occurrence) were lack of energy observed with tegop
Slide 14: MTSOSD-59R: Symptoms getting better (3 of 3)
MTSOSD-59R: Symptoms getting better (3 of 3) Physical For symptoms with the greatest between-group difference in muscle cramp improvement, greater brittle fingernails improvements (i.e. decreased brittle skin symptom occurrence) were observed with tegoprubart than joint pain tacrolimus for: increase
Slide 15: MTSOSD-59R: Symptoms getting worse (1 of 3)
MTSOSD-59R: Symptoms getting worse (1 of 3) Neurological For symptoms with the greatest between-group difference in trembling hands worsening, more symptoms got tingling/numbness in hands/feet worse (i.e. increased symptom hearing loss occurrence) with tacrolimus dizziness than tegoprubart for: nigh
Slide 16: MTSOSD-59R: Symptoms getting worse (2 of 3)
MTSOSD-59R: Symptoms getting worse (2 of 3) Gastrointestinal/metabolic For symptoms with the greatest between-group difference in stomach complain/nausea/vomiting worsening, more symptoms got increased thirst worse (i.e. increased symptom poor appetite occurrence) with tacrolimus diarrhea than tegop
Slide 17: MTSOSD-59R: Symptoms getting worse (3 of 3)
MTSOSD-59R: Symptoms getting worse (3 of 3) Participants with occurence (%) Physical Difference in occurence (%) For symptoms with the greatest between-group difference in palpitation worsening, more symptoms got menstrual problems worse (i.e. increased symptom occurrence) with tacrolimus warmth of
Slide 18: Conclusions
Conclusions • Kidney Disease Quality of Life Short Form (KDQOL-SF) • Improvements from baseline to Month 12 were observed in all 5 KDQOL-SF subscales with tegoprubart and in 4 of 5 subscales with tacrolimus • Improvement with tegoprubart on the symptoms and problems scale was both clinically and sta